CXCL12 and brain infarction: That cerebral infarct volume reduction, identified following exogenous Lin−/Sca1+ cell administration, was abrogated when Lin−/Sca1+ cell administration occurred concomitant to SDF1-A antibody administration provides further support to this hypothesis (Figure 4).